Pharmacogenomics of antiretroviral therapy

Drug Development Research

Volumn 62, Issue 3, 2004, Pages 213-220

  Haas, David W ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Antiretroviral drugs; Pharmacogenomics; Toxicity

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; ATAZANAVIR; CHEMOKINE RECEPTOR CCR5; DIDANOSINE; EFAVIRENZ; EMTRICITABINE; GLYCOPROTEIN P; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RIFAMPICIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA; ZALCITABINE; ZIDOVUDINE;

ABDOMINAL PAIN; ALLELE; ANEMIA; CENTRAL NERVOUS SYSTEM DISEASE; CLINICAL TRIAL; DIARRHEA; DISORIENTATION; DIZZINESS; DREAMING; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG METABOLISM; DRUG RESPONSE; DRUG SAFETY; DRUG TARGETING; FATTY LIVER; FEVER; GENE DELETION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE PHENOTYPE CORRELATION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERBILIRUBINEMIA; INSOMNIA; JAUNDICE; LACTIC ACIDOSIS; LETHARGY; LEUKOPENIA; LIPOATROPHY; LIPODYSTROPHY; LIVER TOXICITY; LONG TERM CARE; LUNG DISEASE; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUTH ULCER; NEPHROLITHIASIS; PANCREATITIS; PERIPHERAL NEUROPATHY; PHARMACODYNAMICS; PHARMACOGENOMICS; PROMOTER REGION; RACE DIFFERENCE; RASH; REVIEW; RISK ASSESSMENT; SIDE EFFECT; SYSTEMATIC REVIEW; TREATMENT OUTCOME; VIRUS REPLICATION;

EID: 10044233991     PISSN: 02724391     EISSN: None     Source Type: Journal    
DOI: 10.1002/ddr.10359     Document Type: Review

References (74)

1. Ariyoshi N, Miyazaki M, Toide K, Sawamura Y, Kamataki T. 2001. A single nucleotide polymorphism of CYP2b6 found in Japanese enhances catalytic activity by antoactivation. Biochem Biophys Res Commun 281:1256-1260.
2. Barrett JS, Joshi AS, Chai M, Ludden TM, Fiske WD, Pieniaszek HJ Jr. 2002. Population pharmacokinetic meta-analysis with efavirenz. Int J Clin Pharmacol Ther 40:507-519.
3. Bastard JP, Caron M, Vidal H, Jan V, Auclair M, Vigouroux C, Luboinski J, Laville M, Maaehi M, Girard PM, Rozenbaum W, Levan P, Capean J. 2002. Association between altered expression of adipogenic factor SREBP1 in lipoatrophic adipose tissue from HIV-1-infected patients and abnormal udipocyte differentiation and insulin resistance. Lancet 359:1026-1031.
4. Becquemont L, Camus M, Eschwege V, Barbu V, Rev E, Funck-Brentano C, Jaillon P. 2000. Lymphocyte P-glycoprotein expression and activity before and after rifampicin in man. Fundam Clin Pharmacol 14:519-525.
5. Beutler E, Gelbart T, Demina A. 1998. Racial variability in the UDP-glucuronosyltransferase 1 (UGT1A1) promoter: a balanced polymorphism for regulation of bilirubin metabolism? Proc Natl Acad Sci USA 95:8170-8174.
6. Brumme ZL, Dong WW, Chan KJ, Hogg RS, Montaner JS, O'Shaughnessy MV, Harrigan PR. 2003. Influence of polymorphisms within the CX3CR1 and MDR-1 genes on initial antiretroviral therapy response. AIDS 17:201-208.
7. Chaudhary PM, Roninson IB. 1991. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell 66:85-94.
8. Choe H, Farzan M, Sun Y, Sullivan N, Rollins B, Ponatli PD, Wu L, Mackay CR, LaRosa G, Newman W, Gerard N, Gerard C, Sodroski J. 1996. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 85:1135-1148.
9. Code EL, Crespi CL, Penman BW, Gonzalez FJ, Chang TK, Waxman DJ. 1997. Human cytochrome P4502B6: interindividual hepatic expression, substrate specificity, and role in procarcinogen activation. Drug Metab Dispos 25:985-993.
10. Csajka C, Marzolini C, Fattinger K, Decosterd LA, Fellay J, Telenti A, Biollax J, Buclin T. 2003. Population pharmacokinetics and effects of efavirenz in patients with human immunodeficiency virus infection. Clin Pharm Ther 73:20-30.
11. Dean M, Carrington M, Winkler C, Huttley GA, Smith MW, Allikmets R, Goedert JJ, Buchbinder SP, Vittinghoff E, Gomperts E, Donfield S, Vlahov D, Kaslow R, Saah A, Rinaldo C, Detels R, O'Brien SJ. 1996. Genetic restriction of HIV-1 infection and progression to AIDS by a deletion allele of the CKR5 structural gene. Hemophilia Growth and Development Study, Multicenter AIDS Cohort Study, Multicenter Hemophilia Cohort Study, San Francisco City Cohort, ALIVE Study. Science 273:1856-1862.
12. Deng H, Liu R, Ellmeier W, Choe S, Unutmaz D, Burkhart M, Di Marzio P, Marmon S, Sutton RE, Hill CM, Davis CB, Peiper SC, Schall TJ, Littman DR, Landau NR. 1996. Identification of a major co-receptor for primary isolates of HIV-1. Nature 381: 661-666.
13. Dragic T, Litwin V, Allaway CP, Martin SR, Huang Y, Nagashima KA, Cayanan C, Maddon PJ, Koup RA, Moore JP, Paxton WA. 1996. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 381:667-673.
14. Evans WE, Johnson JA. 2001. Pharmacogenomics: the inherited basis lor interindividual differences in drug response. Annu Rev Genomics Hum Genet 2:9-39.
15. Evans WE, Belling MV. 1999. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 286: 487-491.
16. Fellay J, Marzolini C, Meaden ER, Back DJ, Buclin T, Chave JP, Decosterd LA, Furrer H, Opravil M, Pantaleo G, Retelska D, Ruiz L, Schinkel AH, Vernazza P, Eap CB, Telenti A, and The Swiss HIV Cohort Study. 2002. Response to antiretroviral treatment in HIV-1-infected individuals with allelic variants of the multidrug resistance transporter 1: a pharmacogenetics study. Lancet 359:30-36.
17. Haas DW, Wilkinson GR, Kuritzkes DR, Richman DD, Nicotera J, Mahon LF, Sutcliffe C, Siminiski S, Andersen J, Coughlin K, Clayton EW, Haines J, Marshak A, Saag M, Lawrence J, Gustavson J, Bennett JA, Christensen R, Matula MA, Wood AJJ. 2003a. A multi-investigator/institutional DNA bank for AIDS-related human genetic studies: AACTG protocol A5128. HIV Clinical Trials 4/5:287-300.
18. Haas DW, Wu H, Li H, Bosch RJ, Lederman MM, Kuritzkes D, Landay A, Connick E, Benson C, Wilkinson GR, Kessler H, Kim RB. 2003b. MDR1 gene polymorphisms and phase 1 viral decay during HIV-1 infection: an adult AIDS Clinical Trials Group study. J Acquir Immune Defic Syndr 34:295-298.
19. Haas DW, Ribando H, Wilkinson GR, Gulick R, Clifford D, Hulgan T, Acosta EP. 2004. A common CYP2B6 variant is associated with efavirenz pharmacokinetics and central nervous system side effects: AACTG study NWCS214. Presented at 11th Conference on Retroviruses and Opportunistic Infections, February 2004, San Francisco, CA.
20. Hajeer AH, Hutchinson IV. 2001. Influence of TNF-alpha gene polymorphisms on TNFalpha production and disease. Hum Immunol 62:1191-1199.
21. Hetherington S, Hughes AR, Mosteller M, Shortino D, Baker KL, Spreen W, Lai E, Davies K, Handley A, Dow DJ, Fling ME, Stocum M, Bowman C, Thurmond LM, Roses AD. 2002. Genetic variations in HLA-B region and hypersensitivity reactions to abacavir. Lancet 359:1121-1122.
22. Hoffmeyer S, Burk O, von Richter O, Arnold H.P, Brockmoller J, Johne A, Cascorbi I, Gerloff T, Roots I, Eichelbaum M, Brinkmann U. 2000. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 97:3473-3478.
23. Huang L, Wring SA, Woolley JL, Bronwer KR, Serabjit-Singh C, Polli JW. 2001. Induction of P-glycoprotein and cytochrome P450 3A by HIV protease inhibitors. Drug Metab Dispos 29: 754-760.
24. Ioannidis JP, Ntzani EE, Trikalinos TA, Contopoulos-Ioannidis DG. 2001. Replication validity of genetic association studies. Nat Genet 29:306-309.
25. Jain KK. 2001. Tech.Sight. Biochips for gene spotting. Science 294:621-623.
26. Jinno H, Tanaka-Kagawa T, Ohno A, Makino Y, Matsushima E, Hanioka N, Ando M. 2003. Functional characterization of cytochrome P450 2B6 allelic variants. Drug Metab Dispos 31:398-403.
27. Kim AE, Dintaman JM, Waddell DS, Silverman JA. 1995a. Saquinavir, an HIV protease inhibitor, is transported by P-glycoprotein. J Pharmacol Exp Ther 286:1439-1445.
28. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR. 1998b. The drug transporter P-glyeoprotein limits oral absorption and brain entiy of HIV-1 protease inhibitors. J Clin Invest 101:289-294.
29. Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, Lan LB, Schuetz JD, Schuetz EG, Wilkinson GR. 2001. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 70:189-199.
30. Kirchheiner J, Klein C, Meineke I, Sasse J, Zanger UM, Murdter TE, Roots I, Brockmoller J. 2003. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 13:619-626.
31. Lamba V, Lamba J, Yasuda K, Strom S, Davila JC, Hancock M, Fackenthal JD, Rogan P, Ring BJ, Wrighton SA, Schuetz EG. 2003. Hepatic CYP2B6 expression: gender and ethnic differences and relationship to CYP2B6 genotype and CAR expression. J Pharmacol Exp Ther 307:906-922.
32. Lang T, Klein K, Fischer J, Nussler AK, Neuhaus P, Hofmann U, Eichelbaum M, Schwab M, Zanger UM. 2001. Extensive genetic polymorphism in the human CYP2B6 gene with impact on expression and function in human liver. Pharmacogenetics 11:399-415.
33. Lee CG, Gottesman MM. 1998. HIV-1 protease inhibitors and the MDR1 multidrug transporter. J Clin Invest 101:287-288.
34. Lee CG, Gottesman MM, Cardarelli CO, Ramachandra M, Jeang KT, Ambudkar SV, Pastan I, Dey S. 1998. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry 37:3594-3601.
35. Liu R, Paxton WA, Choe S, Ceradini D, Martin SR, Horuk R, MacDonald ME, Stuhlmann H, Koup RA, Landau NR. 1996. Homozygons defect in HIV-1 coreceptor accounts for resistance of some multiply-exposed individuals to HIV-1 infection. Cell 86:367-377.
36. Lupo LJ, Maa J-F, Dezil CM, Said D, Bessen L, Hodder S. 2002. Efficacy of efavirenz in different racial groups. Presented at 6th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, November 17-21, 2002.
37. Maher B, Alfirevic A, Vilar FJ, Wilkins EG, Park BK, Pirmohamed M. 2002. TNF-alpha promoter region gene polymorphisms in HIV-positive patients with lipodystrophy AIDS 16:2013-2018.
38. Mallal S, Nolan D, Witt C, Masel G, Martin AM, Moore C, Sayer D, Castley A, Mamotte C, Maxwell D, James I, and Christiansen FT. 2002. Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir. Lancet 359:727-732.
39. Mallal SA, John M, Moore CB, James IR, McKinnon EJ. 2000. Contribution of nucleoside analogue reverse transcriptase inhibitors to subcutaneous fat wasting in patients with HIV infection. AIDS 14:1309-1316.
40. Mangeat B, Turelli P, Caron G, Friedli M, Perrin L, Trono D. 2003. Broad antiretroviral defence by human APOBEC3G through lethal editing of nascent reverse transcripts. Nature 424:99-103.
41. Martin AM, Nolan D, Gaudieri S, Almeida CA, Nolan R, James I, Carvalho F, Phillips E, Christiansen FT, Purcell AW, McCluskey J, Mallal S. 2004. Predisposition to abacavir hypersensitivity conferred by HLA-B*5701 and a haplotypic Hsp70-Hom variant. Proc Natl Acad Sci USA 101:4180-4185.
42. Marzolini C, Telenti A, Decosterd LA, Grenb G, Biollaz J, Buclin T. 2001. Efavirenz plasma levels can predict treatment failure and central nervous system side effects in HIV-1-infected patients.
43. Merikangas KR, Swendsen JD. 1997. Genetic epidemiology of psychiatric disorders. Epidemiol Rev 19:144-155.
44. Nasi M, Borghi V, Pinti M, Bellodi C, Lugli E, Maffei S, Troiano L, Richeldi L, Mussini C, Esposito R, Cossarizza A. 2003. MDR1 G3435T genetic polymorphism does not influence the response to antiretroviral therapy in drug-naive HIV-positive patients. AIDS
45. Nolan D, Moore C, Castley A, Sayer D, Mamotte C, John M, James I, Mallal S. 2003. Tumour necrosis factor-alpha gene -238G/A promoter polymorphism associated with a more rapid onset of lipodystrophy AIDS 17:121-123.
46. O'Mara, et al. 2003. Population pharmacodynamic assessment of atazanavir exposure, uridine diphosphate-glucuronosyl transferase (UGT) 1A1 genotype and safety in healthy subjects. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL. Abstract 3051.
47. Palella FJJ, Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD. 1998. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators [see comments]. N Engl J Med 338:853-860.
48. Perloff MD, von Moltke LL, Fahey JM, Daily JP, Greenblatt DJ. 2000. Induction of P-glycoprotein expression by HIV protease inhibitors in cell culture. AIDS 14:1287-1289.
49. Peyrieere H, Nicolas J, Siffert M, Demoly P, Hillaire-Buys D, Reynes J. 2001. Hypersensitivity related to abacavir in two members of a family. Ann Pharmacother 35:1291-1292.
50. Pfister M, Labbe L, Hammer SM, Mellors J, Bennett KK, Rosenkranz S, Sheiner LB. 2003. Population pharmacokinetics and pharmacodynamics of elavirenz, nelfinavir, and indinavir: Adult AIDS Clinical Trial Group Study 398. Antimicrob Agents Chemother 47:130-137.
51. Phillips KA, Veenstra DL, Oren E, Lee JK, Sadee W. 2001. Potential role of pharmacogenomics in reducing adverse drug reactions: a systematic review. JAMA 286:2270-2279.
52. Physician's Desk Reference. 2004. Efavirenz prescribing information. Physician's Desk Reference. 57th ed. Montvale, NJ: Thompson's PDR. p 1088-1094.
53. Polli JW, Jarrett JL, Studenberg SD, Humphreys JE, Dennis SW, Brouwer KR, Woolley JL. 1999. Role of P-glycoprotein on the CNS disposition of amprenavir (141W94), an HIV protease inhibitor. Pharm Res 16:1206-1212.
54. Profit L, Eagling VA, Back DJ. 1999. Modulation of P-glycoprotein function in human lymphocytes and Caco-2 cell monolayers by HIV-1 protease inhibitors. AIDS 13:1623-1627.
55. Raijmakers MT, Jansen PL, Steegers EA, Peters WH. 2000. Association of human liver bilirubin UDP-glucuronyltransferase activity with a polymorphism in the promoter region of the UGT1A1 gene. J Hepatol 33:348-351.
56. Roses AD. 2000. Pharmacogenetics and the practice of medicine. Nature 405:857-865.
57. Sachidanandam R, Weissman D, Schmidt SC, Kakol JM, Stein LD, Marth G, Sherry S, Mullikin JC, Mortimore BJ, Willey DL, Hunt SE, Cole CC, Coggill PC, Rice CM, Ning Z, Rogers J, Bentley DR, Kwok PY, Mardis ER, Yeh RT, Schultz B, Cook L, Davenport R. Dante M, Fulton L, Millier L, Waterston RH, McPherson JD, Gilman B, Schaffner S. Van Etten WJ, Reich D, Higgins J, Daly MJ, Blumenstiel B, Baldwin J, Stange-Thomann N, Zody MC, Linton L, Lander ES, Altshuler D. 2001. A map of human genome sequence variation containing 1.42 million single nucleotide polymorphisms. Nature 409:928-933.
58. Samson M, Libert F, Doranz BJ, Rucker J, Liesnard C, Farber CM, Saragosti S, Lapoumeroulie C, Cognaux J, Forceille C, Muyldermans G, Verhofstede C, Burtouboy G, Georges M, Imai T, Rana S, Yi Y, Smyth RJ, Collman RG, Doms RW, Vassart G, Parmentier M. 1996. Resistance to HIV-1 infection in Caucasian individuals hearing mutant alleles of the CCR-5 chemokine receptor gene. Nature 382:722-725.
59. Sethi JK, Hotamisligil GS. 1999. The role of TNF alpha in adipocyte metabolism. Semin Cell Dev Biol 10:19-29.
60. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J Pharmacol Exp Ther 270:414-423.
61. Shiraki N, Hamada A, Yasnda K, Fujii J, Arimori K, Nakano M. 2000. Inhibitory effect of human immunodeficiency virus protease inhibitors on multidrug resistance transporter P-glycoproteins. Biol Pharmaceut Bull 23:1528-1531.
62. Srinivas RV, Middlemas D, Flynn P, Fridland A. 1998. Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother 42:3157-3162.
63. Staszewski S, Morales-Ramirez J, Tashima KT, Rachlis A. Skiest D, Stanford J, Stryker R, Johnson P, Labriola DF, Farina D, Manion DJ, Ruiz NM. 1999. Efavirenz. plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HlV-1 infection in adults. Study 006 Team. N Engl J Med 341:1865-1873.
64. Strassburg CP, Manns MP 2000. Jaundice genes and promoters. J Hepatol 33:476-479. Stremlaui M, Owens CM, Perron MJ, Kiessling M, Autissier P, Sodroski J. 2004. The cytoplasmic body component TRIM5-alpha restricts HlV-1 infection in Old World monkeys. Nature 427:848-853.
65. Stresser DM, Kupfer D. 1999. Monospecific antipepticle antibody to cytochrome P-450 2B6. Drug Metab Dispos 27:517-525.
66. Symonds W, Cutrell A, Edwards M, Steel H, Spreen B, Powell G, McGuirk S, Hetherington S. 2002. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther 24:565-573.
67. Syvanen AC. 2001. Accessing genetic variation: genotyping single nucleoticle polymorphisms. Nat Rev Genet 2:930-942.
68. The Panel on Clinical Practices for Treatment of HIV Infection. Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents. 2003 [cited 2003 Dee 5] Available from: URL: http://www.aidsinfo. nih.gov/guidelines.
69. Venter JC, Adams MD, Myers EW. et al. 2001. The sequence of the human genome. Science 291:1304-1351.
70. Ward BA, Gorski JC, Jones DR, Hall SD, Flockhart DA, Desta Z. 2003. The cytochrome P450 2136 (CYP2B6) is the main catalyst of efavirenx primary and secondary metabolism: implication for HIV/AIDS therapy and utility of efavirenz as a substrate marker of CYP2B6 catalytic activity, J Pharmacol Exp Ther 306:287-300.
71. Washington CB, Duran GE, Man MC, Sikic BI, Blaschke TF. 1998. Interaction of anti-HIV protease inhibitors with the multidrug transporter P-glycoprotein (P-gp) in human cultured cells. J Acq Immune Def Syndr 19:203-209.
72. Washington CB, Wiltshire HR. Man M, Moy T, Harris SR, Worth E, Weigl P, Liang Z, Hall D, Marriott L, Blaschke TF. 2000. The disposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab Dispos 28:1058-1062.
73. Wegner S, Vahey VI, Dolan M, et al. Racial differences in clinical efficacy ol elavirenz-hased antiretroviral therapy. Presented at 9th Conference on Retroviruses and Opportunistic Infections, Seattle, WA, February 4-8, 2002.
74. Zucker SD, Qiu X, Rouster SD, Yu F, Green RM, Keshavan P, Feinberg J, Sherman KE. 2001. Mechanism of indinavir-induced hyperbilirubinemia. Proc Natl Acad Sci USA 98:12671-12676.